SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: Neurogen (NRGN)

No earlier versions found for this Subject.


Return to Neurogen (NRGN)
 
This Connecticut firm has alliances with Pfizer and Schering on technology leads in treating obesity and psychiatric illnesses. One of the few biotechs with a reasonable P/E of 16. Also perceived to have excellent, proprietary science in combinatorial chemistry (from which it got those ob/psych leads - more should come.)

Given the recent softness in biotech overall, it appears to be an excellent buy. Does anyone have additional insights, information or opinions?

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News